US5202117A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating thrombi with g-csf
Assignee: Chugai Pharmaceutical Co Ltd
•
Filing: 1989-08-22
•
Granted: 1993-04-13
•
Expires: 2009-08-22
Abstract
Abstract A thrombus control agent is disclosed which comprises a human granulocyte colony stimulating factor (human G-CSF) as an active ingredient and a pharmaceutically acceptable carrier. This thrombus control agent can be administered to a patient bearing thrombi formed in the arterial and venous vessels. Furthermore, the use of human G-CSF for preparing the thrombus control agent is disclosed. The inventors found that human G-CSF is useful for treating thrombi and developed the use of human G-CSF for this purpose although nobody has clearly reported this type of pharmacological activity of human G-CSF.
Inventors
- 👤 Koichiro Tsuji
- 👤 Masayoshi Ono
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 14:02
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/14; C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/53; C07K14/535
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
66 words
A method for the dissolution of thrombi in a mammal which comprises: (a) providing a composition comprising purified human granulocyte colony stimulating factor (G-CSF) in a pharmaceutically-acceptable medium; and (b) administering the composition to the mammal:wherein the G-CSF is present in the composition in an amount sufficient to increase the production of plasminogen activator activity in the blood so as to lyse fibrin and dissolve thrombi.
Claim 2
Independent Claim
66 words
A method for the dissolution of thrombi in a mammal which comprises: (a) providing a composition comprising purified human granulocyte colony stimulating factor (G-CSF) in a pharmaceutically-acceptable medium; and (b) administering the composition to the mammal:wherein the G-CSF is present in the composition in an amount sufficient to increase the production of plasminogen activator activity in the blood so as to lyse fibrin and dissolve thrombi.
Claim 3
Dependent Claim
13 words
The method according to claim 1, wherein the composition is administered by injection.
Claim 4
Dependent Claim
32 words
The method according to claim 1 or claim 2, wherein the composition is administered such that 0.1 μg-1,000 μg of G-CSF is delivered to the mammal one to seven times per week.
Claim 5
Dependent Claim
29 words
The method according to claim 3, wherein the composition is administrated such that 0.1 μg-500 μg of G-CSF is delivered to the mammal one to seven times per week.
Claim 6
Dependent Claim
28 words
The method according to claim 1 or claim 2, wherein the composition is administrated in a dose of 1 μg-10 μg of G-CSF per kg of body weight.
Claim 7
Dependent Claim
18 words
The method according to claim 1, wherein the granulocyte colony stimulating factor is provided using recombinant gene technology.
Claim 8
Independent Claim
60 words
A method for increasing fibrinolytic activity in blood which comprises: (a) providing a composition comprising purified human granulocyte colony stimulating factor (G-CSF) in a pharmaceutically-acceptable medium; and (b) administering the composition to the mammal:wherein the G-CSF is present in the composition in an amount sufficient to increase the production of plasminogen activator activity in the blood, thereby increasing fibrinolytic activity.
Claim 9
Independent Claim
60 words
A method for increasing fibrinolytic activity in blood which comprises: (a) providing a composition comprising purified human granulocyte colony stimulating factor (G-CSF) in a pharmaceutically-acceptable medium; and (b) administering the composition to the mammal:wherein the G-CSF is present in the composition in an amount sufficient to increase the production of plasminogen activator activity in the blood, thereby increasing fibrinolytic activity.
Claim 10
Dependent Claim
60 words
The method according to claim 7 for control of venous and arterial thrombi by increasing fibrinolytic activity:wherein the composition comprises about 50-100 μg/ml of human granulocyte colony stimulating factor in 10 mM phosphate buffer and about 0.1 mg/ml of a pharmaceutically acceptable nonionic surfactant:and wherein G-CSF enhances the production of plasminogen activator which is capable of activating the fibrinolytic system.
Claim 11
Dependent Claim
22 words
The method according to claim 8 wherein the nonionic surfactant is selected from the group consisting of polyoxyethylenesorbitan monolaurate and polyoxyethylenesorbitan monooleate.
Claim 12
Dependent Claim
22 words
The method according to claim 8 which further comprises about 10 mg/ml of human serum albumin and about 50 mg/ml of mannitol.
Claim 13
Dependent Claim
20 words
The method according to claim 8 which further comprises about 10 mg/ml of gelatin and about 50 mg/ml of mannitol.
Claim 14
Independent Claim
59 words
A method of increasing plasminogen activator activity in a mammal for dissolution of venous and arterial thrombi, comprising administering to the mammal a composition of purified human granulocyte colony stimulating factor (G-CSF) in a pharmaceutically-acceptable medium; wherein the G-CSF in the composition is present in an amount sufficient to promote increased production of plasminogen activator activity to dissolve thrombi.
Claim 15
Independent Claim
59 words
A method of increasing plasminogen activator activity in a mammal for dissolution of venous and arterial thrombi, comprising administering to the mammal a composition of purified human granulocyte colony stimulating factor (G-CSF) in a pharmaceutically-acceptable medium; wherein the G-CSF in the composition is present in an amount sufficient to promote increased production of plasminogen activator activity to dissolve thrombi.
Claim 16
Dependent Claim
13 words
The method according to claim 12, wherein the composition is administered by injection.
Claim 17
Dependent Claim
32 words
The method according to claim 12 or claim 13, wherein the composition is administered such that 0.1 μg-1,000 μg of G-CSF is delivered to the mammal one to seven times per week.
Claim 18
Dependent Claim
29 words
The method according to claim 14, wherein the composition is administrated such that 0.1 μg-500 μg of G-CSF is delivered to the mammal one to seven times per week.
Claim 19
Dependent Claim
28 words
The method according to claim 12 or claim 13, wherein the composition is administrated in a dose of 1 μg-10 μg of G-CSF per kg of body weight.
Claim 20
Dependent Claim
18 words
The method according to claim 12, wherein the granulocyte colony stimulating factor is provided using recombinant gene technology.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-12 | 1996-10-12 | 1997-04-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-12 | 2000-10-12 | 2001-04-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-12 | 2004-10-12 | 2005-04-13 | $7700.00 | Window Closed / Lapsed |